Steven P Balk

List of Publications by Year
in descending order

129 papers	12,871 citations	29994 54 h-index	23472 111 g-index
134 all docs	134 docs citations	134 times ranked	13251 citing authors

#	Article	IF	Citations
1	Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer. New England Journal of Medicine, 1995, 332, 1393-1398.	13.9	1,144
2	Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer. Cancer Research, 2006, 66, 2815-2825.	0.4	967
3	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. Cell, 2009, 138, 245-256.	13.5	797
4	Extreme Th1 bias of invariant VÎ±24JÎ±Q T cells in type 1 diabetes. Nature, 1998, 391, 177-181.	13.7	639
5	Biology of Prostate-Specific Antigen. Journal of Clinical Oncology, 2003, 21, 383-391.	0.8	524
6	Requirements for CD1d Recognition by Human Invariant VÎ±24+ CD4â^'CD8â^' T Cells. Journal of Experimental Medicine, 1997, 186, 109-120.	4.2	509
7	Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production. Immunity, 2012, 37, 574-587.	6.6	419
8	Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1. Cancer Cell, 2011, 20, 457-471.	7.7	387
9	Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors. Cancer Research, 2011, 71, 6503-6513.	0.4	383
10	Loss of IFN-Î³ Production by Invariant NK T Cells in Advanced Cancer. Journal of Immunology, 2001, 167, 4046-4050.	0.4	343
11	AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling, 2008, 6, nrs.06001.	1.0	300
12	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. Journal of Clinical Investigation, 2018, 129, 192-208.	3.9	266
13	Androgens Induce Prostate Cancer Cell Proliferation through Mammalian Target of Rapamycin Activation and Post-transcriptional Increases in Cyclin D Proteins. Cancer Research, 2006, 66, 7783-7792.	0.4	260
14	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	0.8	220
15	Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor. Journal of Biological Chemistry, 2002, 277, 26321-26326.	1.6	203
16	Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells. Nature, 1981, 289, 139-144.	13.7	202
17	Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15969-15974.	3.3	183
18	Tyrosine Kinases Expressed in Vivo by Human Prostate Cancer Bone Marrow Metastases and Loss of the Type 1 Insulin-Like Growth Factor Receptor. American Journal of Pathology, 1999, 155, 1271-1279.	1.9	172

#	Article	IF	Citations
19	Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer. Clinical Cancer Research, 2014, 20, 1590-1600.	3.2	165
20	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. Clinical Cancer Research, 2015, 21, 1273-1280.	3.2	152
21	Reactivation of Androgen Receptorâ€"Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate Cancer. Cancer Research, 2009, 69, 6027-6032.	0.4	141
22	Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature, 2016, 533, 547-551.	13.7	138
23	SOX9 drives WNT pathway activation in prostate cancer. Journal of Clinical Investigation, 2016, 126, 1745-1758.	3.9	138
24	Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell, 2020, 38, 279-296.e9.	7.7	135
25	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrine-Related Cancer, 2011, 18, R175-R182.	1.6	131
26	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clinical Cancer Research, 2017, 23, 3510-3519.	3.2	130
27	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell, 2019, 35, 401-413.e6.	7.7	127
28	AR and ER Interaction with a p21-Activated Kinase (PAK6). Molecular Endocrinology, 2002, 16, 85-99.	3.7	119
29	EZH2 inhibition activates a dsRNAâ€"STINGâ€"interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	5.7	118
30	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. Cell Reports, 2014, 9, 1618-1627.	2.9	115
31	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 2017, 7, 750-765.	7.7	112
32	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
33	Identification of hypoxia-inducible factor-1? (HIF-1?) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate, 2005, 63, 215-221.	1.2	98
34	Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation. Journal of Biological Chemistry, 2012, 287, 8571-8583.	1.6	94
35	Transcriptional mediators of treatment resistance in lethal prostate cancer. Nature Medicine, 2021, 27, 426-433.	15.2	90
36	CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8874-8879.	3.3	89

#	Article	IF	Citations
37	Selective activation, expansion, and monitoring of human iNKTâ€„cells with a monoclonal antibody specific for the TCR Î±â€chain CDR3 loop. European Journal of Immunology, 2008, 38, 1756-1766.	1.6	89
38	Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4. Cancer Research, 2013, 73, 1050-1055.	0.4	85
39	Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110Î² and p110Î´ Catalytic Subunits. Journal of Biological Chemistry, 2010, 285, 14980-14989.	1.6	82
40	Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. Clinical Cancer Research, 2014, 20, 4075-4085.	3.2	81
41	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
42	The altered expression of MiRâ€221/â€222 and MiRâ€23b/â€27b is associated with the development of human castration resistant prostate cancer. Prostate, 2012, 72, 1093-1103.	1.2	79
43	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nature Genetics, 2020, 52, 1011-1017.	9.4	78
44	Recruitment of Î²-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells. Molecular Endocrinology, 2004, 18, 2388-2401.	3.7	77
45	Expression of PD-L1 in Hormone-naÃ¯ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	3.2	77
46	PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival. Cancer Discovery, 2014, 4, 942-955.	7.7	75
47	Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. , 1999, 86, 689-696.		71
48	Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer. Clinical Cancer Research, 2007, 13, 2100-2108.	3.2	71
49	ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Research, 2020, 80, 2094-2100.	0.4	71
50	Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate, 2008, 68, 1510-1516.	1.2	69
51	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Reports, 2016, 17, 966-976.	2.9	66
52	Activation of Î²-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-Î²-Catenin Interaction. Molecular and Cellular Biology, 2006, 26, 929-939.	1.1	65
53	Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide. PLoS ONE, 2010, 5, e11311.	1.1	57
54	The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells. Journal of Urology, 2015, 193, 690-698.	0.2	57

#	Article	IF	Citations
55	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chemico-Biological Interactions, 2015, 234, 332-338.	1.7	57
56	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Research, 2018, 78, 4716-4730.	0.4	56
57	Activation of p21-activated Kinase 6 by MAP Kinase Kinase 6 and p38 MAP Kinase. Journal of Biological Chemistry, 2005, 280, 3323-3330.	1.6	46
58	Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 426-439.	3.2	46
59	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	3.2	46
60	Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nature Communications, 2021, 12, 7308.	5.8	46
61	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chemical Biology, 2021, 28, 134-147.e14.	2.5	44
62	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clinical Cancer Research, 2017, 23, 3823-3833.	3.2	43
63	Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clinical Cancer Research, 2018, 24, 5458-5470.	3.2	43
64	Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 6354-6362.	0.4	42
65	Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects. Clinical Immunology, 2011, 140, 184-195.	1.4	41
66	ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 3672-3682.	3.2	39
67	Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells. Journal of Immunology, 2008, 180, 7287-7293.	0.4	38
68	Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-13.	1.5	36
69	Targeting the androgen receptor and overcoming resistance in prostate cancer. Current Opinion in Oncology, 2019, 31, 175-182.	1.1	36
70	Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.. Journal of Clinical Oncology, 2012, 30, 4521-4521.	0.8	36
71	Activation of Nonreceptor Tyrosine Kinase Bmx/Etk Mediated by Phosphoinositide 3-Kinase, Epidermal Growth Factor Receptor, and ErbB3 in Prostate Cancer Cells. Journal of Biological Chemistry, 2007, 282, 32689-32698.	1.6	32
72	MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. ELife, 2020, 9, .	2.8	32

#	Article	IF	Citations
73	Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2017, 23, 4592-4601.	3.2	31
74	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 935-945.	3.2	30
75	Intraepithelial Lymphocytes and Their Recognition of Non-Classical MHC Molecules. International Reviews of Immunology, 1994, 11, 15-30.	1.5	29
76	Positive feedback loop mediated by protein phosphatase 1Î± mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Research, 2017, 45, gkw1291.	6.5	28
77	Evidence of T cell receptor Î²-chain patterns in inflammatory and noninflammatory bowel disease states. American Journal of Physiology - Renal Physiology, 1999, 276, G613-G621.	1.6	24
78	Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. Cancer Discovery, 2019, 9, 1490-1492.	7.7	24
79	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Reports, 2021, 36, 109665.	2.9	24
80	Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival. Experimental Hematology, 2008, 36, 464-472.	0.2	23
81	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
82	Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Science Signaling, 2013, 6, ra40.	1.6	21
83	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research, 2021, 27, 4836-4847.	3.2	20
84	Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget, 2016, 7, 1754-1764.	0.8	20
85	Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Letters, 2018, 438, 97-104.	3.2	19
86	ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer Research, 2019, 79, 5260-5271.	0.4	19
87	Androgen receptor epigenetics. Translational Andrology and Urology, 2013, 2, 148-157.	0.6	19
88	Taxane Resistance in Prostate Cancer Mediated by AR-Independent GATA2 Regulation of IGF2. Cancer Cell, 2015, 27, 158-159.	7.7	17
89	Isolation and Functional Use of Human NKT Cells. Current Protocols in Immunology, 2017, 119, 14.11.1-14.11.20.	3.6	17
90	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Research, 2018, 78, 5203-5215.	0.4	16

#	Article	IF	Citations
91	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	2.0	16
92	Reprogramming to resist. Science, 2017, 355, 29-30.	6.0	15
93	Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2103-2105.	0.8	15
94	Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Research, 2022, 82, 1518-1533.	0.4	15
95	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 1, 1-11.	1.5	13
96	Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer and Prostatic Diseases, 2019, 22, 560-568.	2.0	13
97	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6001-6011.	3.2	13
98	Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Letters, 2021, 519, 172-184.	3.2	13
99	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers, 2022, 14, 51.	1.7	12
100	Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate, 2016, 76, 1227-1236.	1.2	11
101	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2022, 28, 3509-3525.	3.2	11
102	Modeling Androgen Deprivation Therapyâ€“Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	1.5	10
103	Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Molecular Therapy, 2022, 30, 1628-1644.	3.7	10
104	Initiation and Evolution of Early Onset Prostate Cancer. Cancer Cell, 2018, 34, 874-876.	7.7	9
105	Calcium signaling: an underlying link between cardiac disease and carcinogenesis. Cell and Bioscience, 2018, 8, 39.	2.1	9
106	Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. American Journal of Hematology, 2019, 94, 62-73.	2.0	9
107	Doxycycline Regulated Induction of AKT in Murine Prostate Drives Proliferation Independently of p27 Cyclin Dependent Kinase Inhibitor Downregulation. PLoS ONE, 2012, 7, e41330.	1.1	9
108	Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget, 2015, 6, 12383-12391.	0.8	9

#	Article	IF	Citations
109	Androgen receptor functions in prostate cancer development and progression. Asian Journal of Andrology, 2014, 16, 561.	0.8	9
110	MHC evolution. Nature, 1995, 374, 505-506.	13.7	7
111	Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precision Oncology, 2021, 5, 1514-1522.	1.5	6
112	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 274-274.	0.8	6
113	Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?. JAMA Oncology, 2015, 1, 577.	3.4	5
114	Specific reversal of cytolytic T lymphocyte - target cell interaction. Journal of Supramolecular Structure and Cellular Biochemistry, 1981, 16, 43-52.	1.4	3
115	Neoadjuvant androgen pathway suppression prior to prostatectomy.. Journal of Clinical Oncology, 2012, 30, 4520-4520.	0.8	3
116	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	1.7	1
117	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2014, 32, TPS2641-TPS2641.	0.8	1
118	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 5013-5013.	0.8	1
119	A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS341-TPS341.	0.8	1
120	A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. JCO Precision Oncology, 2022, 6, e2100091.	1.5	1
121	Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate, 2022, 82, 883-893.	1.2	1
122	Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model. Cancer Immunology, Immunotherapy, 2022, , .	2.0	1
123	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. Blood, 2005, 106, 5183-5183.	0.6	0
124	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. Blood, 2006, 108, 5104-5104.	0.6	0
125	Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. Journal of Clinical Oncology, 2014, 32, 5015-5015.	0.8	0
126	Fine tuning metabolism of biochemically active abiraterone metabolites to optimize anti-androgen therapy in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5016-5016.	0.8	0

#	Article	IF	Citations
127	Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer.. Journal of Clinical Oncology, 2017, 35, 98-98.	0.8	0
128	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. Journal of Clinical Oncology, 2019, 37, 151-151.	0.8	0
129	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 174-174.	0.8	0